Clinical Trial Update: CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating quizartinib in combination with chemotherapy for newly diagnosed pediatric FLT3-ITD+ and NPM1wt acute myeloid leukemia; curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Chemotherapy (chemotherapy)
• Quizartinib (Quizartinib)

Snippet

Sponsor: Princess Maxima Center for Pediatric Oncology | Conditions: Acute Myeloid Leukemia in Children | Phase 2 | Status: RECRUITING